Target intelligence / Profile preview

Polycystin-2-like protein 2 (PKD2L2)

Target
PKD2L2
Molecular classification
Ion channel, Transient receptor potential (TRP) channel, Transmembrane protein
01

Overview

Polycystin-2-like protein 2 (PKD2L2) is a member of the transient receptor potential (TRP) channel superfamily, specifically the polycystin (TRPP) subfamily. It is a predicted non-selective cation channel that may function as a calcium-permeable channel in cellular membranes, particularly in primary cilia and possibly involved in mechanical stimulus detection. PKD2L2 has strong homology to the canonical polycystin-2 (PKD2), which is well established in the pathogenesis of autosomal dominant polycystic kidney disease, but PKD2L2 itself is not directly implicated in major human diseases. The protein likely forms tetrameric channels and shares structural features (such as the mucolipin domain) with other TRPP channels. Functionally, it is thought to participate in cellular signaling processes regulated by changes in intracellular calcium, though its physiological role in humans remains incompletely understood. Amiloride can inhibit its channel activity in experimental models, but no therapies targeting PKD2L2 are in clinical use.

Other names
Polycystin-2L2Polycystin-L2TRPP5Polycystic kidney disease 2-like 2 proteinTransient receptor potential cation channel subfamily P member 5
02

Mechanism of action

Channel inhibition (e.g., amiloride blocks cation flow through the channel in experimental systems)

03

Biological functions

Regulation of cation (calcium and possibly sodium, potassium) transport across membranesDetection of mechanical stimuliLikely contributes to signal transduction in primary cilia
04

Disease associations

Polycystic kidney disease (rare/less established compared to PKD2)Other (no specific disease associations are robustly documented; PKD2L2 itself is not definitively linked to major diseases)
05

Safety considerations

None currently known; PKD2L2 is not a mainstream drug target
06

Interacting drugs

Amiloride (not clinically used for this target, but shown to inhibit its channel activity in vitro)
07

Biomarkers

None established for clinical use

Beyond the preview

Go deeper on Polycystin-2-like protein 2 (PKD2L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polycystin-2-like protein 2 (PKD2L2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call